Sitagliptin has been approved for:
A) Monotherapy in once-daily doses
B) Combination therapy with metformin
C) Both 1 and 2
D) Neither 1 nor 2
Correct Answer:
Verified
Q8: Administration of exenatide is by subcutaneous injection:
A)Thirty
Q9: GLP-1 agonists:
A)Directly bind to a receptor in
Q10: Hypoglycemia can result from the action of
Q11: Which characteristic of metformin makes it a
Q12: The decision may be made to switch
Q13: The action of gliptins is different from
Q14: All of the following are options for
Q16: Angiotensin-converting enzyme (ACE) inhibitors are considered renal-protective
Q17: Avoid concurrent administration of exenatide with which
Q18: Lispro is an insulin analogue produced by
Unlock this Answer For Free Now!
View this answer and more for free by performing one of the following actions
Scan the QR code to install the App and get 2 free unlocks
Unlock quizzes for free by uploading documents